- Home
- ENVB vs ACON Comparison
ENVB vs ACON Comparison
Compare ENVB & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- ACON
- Stock Information
- Founded
- ENVB 1994
- ACON 2008
- Country
- ENVB United States
- ACON United States
- Employees
- ENVB N/A
- ACON N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- ENVB Health Care
- ACON Technology
- Exchange
- ENVB Nasdaq
- ACON Nasdaq
- Market Cap
- ENVB 3.0M
- ACON 3.6M
- IPO Year
- ENVB N/A
- ACON 2022
- Fundamental
- Price
- ENVB $5.63
- ACON $5.91
- Analyst Decision
- ENVB Strong Buy
- ACON Buy
- Analyst Count
- ENVB 1
- ACON 2
- Target Price
- ENVB $120.00
- ACON $22.00
- AVG Volume (30 Days)
- ENVB 128.8K
- ACON 22.2K
- Earning Date
- ENVB 11-14-2025
- ACON 11-12-2025
- Dividend Yield
- ENVB N/A
- ACON N/A
- EPS Growth
- ENVB N/A
- ACON N/A
- EPS
- ENVB N/A
- ACON N/A
- Revenue
- ENVB N/A
- ACON $67,483.00
- Revenue This Year
- ENVB N/A
- ACON $145.39
- Revenue Next Year
- ENVB N/A
- ACON $145.45
- P/E Ratio
- ENVB N/A
- ACON N/A
- Revenue Growth
- ENVB N/A
- ACON 36.91
- 52 Week Low
- ENVB $4.88
- ACON $5.90
- 52 Week High
- ENVB $96.30
- ACON $3,499.49
- Technical
- Relative Strength Index (RSI)
- ENVB 59.55
- ACON 28.99
- Support Level
- ENVB $4.88
- ACON $7.20
- Resistance Level
- ENVB $6.10
- ACON $7.33
- Average True Range (ATR)
- ENVB 0.90
- ACON 0.29
- MACD
- ENVB -0.19
- ACON -0.16
- Stochastic Oscillator
- ENVB 20.64
- ACON 11.06
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.